{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T11:22:00Z","timestamp":1785669720301,"version":"3.56.0"},"reference-count":93,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has considerably increased over the last years. NAFLD is currently the most common cause of chronic liver disease in the developing world. The diagnosis of NAFLD\/NASH is often incidental, as the early-stage of disease is frequently free of symptoms. Most patients recognized with NAFLD have severe obesity and other obesity-related disease such as type 2 diabetes mellitus (T2DM), insulin-resistance, dyslipidemia and hypertension. The only proven method for NAFLD improvement and resolution is weight loss. Bariatric surgery leads to significant and long-term weight loss as well as improvement of coexisting diseases. There is a lot of evidence suggesting that metabolic\/bariatric surgery is an effective method of NAFLD treatment that leads to reduction in steatosis, hepatic inflammation and fibrosis. However, there is still a need to perform long-term studies in order to determine the role of bariatric surgery as a treatment option for NAFLD and NASH. This review discusses current evidence about epidemiology, pathogenesis and treatment options for NAFLD including bariatric\/metabolic surgery and its effect on improvement and resolution of NAFLD.<\/jats:p>","DOI":"10.3390\/jcm10245721","type":"journal-article","created":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T11:00:23Z","timestamp":1638874823000},"page":"5721","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric\/Metabolic Surgery as Its Treatment Option: A Review"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3952-3154","authenticated-orcid":false,"given":"Paulina","family":"G\u0142uszy\u0144ska","sequence":"first","affiliation":[{"name":"Department of General and Endocrine Surgery, Medical University of Bialystok, 15-089 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Lemancewicz","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy, Medical University of Bialystok, 15-089 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz Bogdan","family":"Dzi\u0119cio\u0142","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy, Medical University of Bialystok, 15-089 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hady","family":"Razak Hady","sequence":"additional","affiliation":[{"name":"Department of General and Endocrine Surgery, Medical University of Bialystok, 15-089 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: A review of available epidemiological data","volume":"58","author":"Blachier","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7150\/ijbs.29599","article-title":"Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer","volume":"15","author":"Divella","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Calzadilla Bertot, L., and Adams, L.A. (2016). The Natural Course of Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050774"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/lt.25657","article-title":"Nonalcoholic steatohepatitis after liver transplantation","volume":"26","author":"Cotter","year":"2020","journal-title":"Liver Transpl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13358","article-title":"2018 Annual report of the European Liver Transplant Registry (ELTR)\u201450-year evolution of liver transplantation","volume":"31","author":"Adam","year":"2018","journal-title":"Transpl. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e0214","DOI":"10.1097\/MD.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rheinwalt, K.P., Drebber, U., Schierwagen, R., Klein, S., Neumann, U.P., Ulmer, T.F., Plamper, A., Kroh, A., Schipper, S., and Odenthal, M. (2020). Baseline Presence of NAFLD Predicts Weight Loss after Gastric Bypass Surgery for Morbid Obesity. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113430"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5023157","DOI":"10.1155\/2020\/5023157","article-title":"The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods","volume":"2020","author":"Soresi","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2213-8587(13)70218-3","article-title":"Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery","volume":"2","author":"Madsbad","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_14","first-page":"404","article-title":"Epidemiology of nonalcoholic fatty liver disease in Europe: A systematic review and meta-analysis","volume":"34","author":"Cholongitas","year":"2021","journal-title":"Ann. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Italian Association for the Study of the Liver (AISF) (2017). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig. Liver Dis., 49, 471\u2013483.","DOI":"10.1016\/j.dld.2017.01.147"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1194\/jlr.R066357","article-title":"Lipotoxic lethal and sublethal stress signaling in hepatocytes: Relevance to NASH pathogenesis","volume":"57","author":"Hirsova","year":"2016","journal-title":"J. Lipid. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcmgh.2014.11.005","article-title":"Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis","volume":"1","author":"Hirsova","year":"2015","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders","volume":"17","author":"Vigliotti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2010.11.049","article-title":"Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency","volume":"140","author":"Spencer","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/j.gastro.2016.06.022","article-title":"Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol","volume":"151","author":"Rahman","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.12938\/bmfh.18-018","article-title":"The effects of bariatric surgery on gut microbiota in patients with obesity: A review of the literature","volume":"38","author":"Ulker","year":"2019","journal-title":"Biosci. Microbiota Food Health"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ciob\u00e2rc\u0103, D., C\u0103toi, A.F., Cop\u0103escu, C., Miere, D., and Cri\u0219an, G. (2020). Bariatric Surgery in Obesity: Effects on Gut Microbiota and Micronutrient Status. Nutrients, 12.","DOI":"10.3390\/nu12010235"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/hbsn.2019.10.35","article-title":"PNPLA3 and nonalcoholic fatty liver disease: Towards personalized medicine for fatty liver","volume":"9","author":"Yuan","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1093\/hmg\/ddp357","article-title":"The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver","volume":"18","author":"Beer","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jgh.12271","article-title":"Characteristics and diagnosis of NAFLD\/NASH","volume":"28","author":"Hashimoto","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_32","unstructured":"Pujitha, K., and Savio, J. (2021). Nonalcoholic Fatty Liver, StatPearls Publishing."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.3748\/wjg.v20.i22.6821","article-title":"Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease","volume":"20","author":"Khov","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_34","first-page":"CR735","article-title":"The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease","volume":"18","author":"Swatek","year":"2012","journal-title":"Med. Sci. Monit."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Schmitz, S.M., Kroh, A., Ulmer, T.F., Andruszkow, J., Luedde, T., Brozat, J.F., Neumann, U.P., and Alizai, P.H. (2020). Evaluation of NAFLD and fibrosis in obese patients\u2014A comparison of histological and clinical scoring systems. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01400-1"},{"key":"ref_36","first-page":"147","article-title":"Non-alcoholic fatty liver disease: An update on diagnosis","volume":"91","author":"Dumitrascu","year":"2018","journal-title":"Clujul Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jmri.22580","article-title":"Quantitative Assessment of Liver Fat with Magnetic Resonance Imaging and Spectroscopy","volume":"34","author":"Reeder","year":"2011","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/17512433.2017.1299573","article-title":"Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"10","author":"Han","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2036.2012.05121.x","article-title":"Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease\u2014MRI accurately quantifies hepatic steatosis in NAFLD","volume":"36","author":"Permutt","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.3748\/wjg.v16.i42.5286","article-title":"Histopathology of nonalcoholic fatty liver disease","volume":"16","author":"Brunt","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.32074\/1591-951X-242","article-title":"Pathology of non-alcoholic fatty liver disease","volume":"113","author":"Cataldo","year":"2021","journal-title":"Pathologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/MCG.0b013e3181dd1348","article-title":"Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease","volume":"45","author":"Juluri","year":"2011","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_45","first-page":"189","article-title":"A Comparison of Brunt\u2019s Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging","volume":"34","author":"Purcell","year":"2015","journal-title":"Puerto Rico Health Sci. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Jeznach-Steinhagen, A., Ostrowska, J., Czerwonogrodzka-Senczyna, A., Boniecka, I., Shahnazaryan, U., and Kury\u0142owicz, A. (2019). Dietary and Pharmacological Treatment of Nonalcoholic Fatty Liver Disease. Medicina, 55.","DOI":"10.3390\/medicina55050166"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Dudekula, A., Rachakonda, V., Shaik, B., and Behari, J. (2014). Weight loss in nonalcoholic Fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0111808"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fendo.2014.00164","article-title":"Bariatric surgery and non-alcoholic Fatty liver disease: Current and potential future treatments","volume":"5","author":"Sasaki","year":"2014","journal-title":"Front. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"108984","DOI":"10.1016\/j.diabres.2021.108984","article-title":"Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: Clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial","volume":"178","author":"Russo","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to Pioglitazone in Patients with Nonalcoholic Steatohepatitis with vs without Type 2 Diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/S0168-8278(15)30002-7","article-title":"Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicenter, double-blinded, randomized, placebo-controlled phase II trial","volume":"62","author":"Armstrong","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.2147\/DDDT.S224688","article-title":"Liraglutide Improves Non-Alcoholic Fatty Liver Disease in Diabetic Mice by Modulating Inflammatory Signaling Pathways","volume":"13","author":"Luo","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fphar.2020.00432","article-title":"Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/dmrr.2713","article-title":"Comparative efficacy of anti-diabetic agents on NAFLD in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized and non-randomized studies","volume":"32","author":"Tang","year":"2016","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","article-title":"Clinical trial: Pilot study of metformin for the treatment of non-alcoholic steatohepatitis","volume":"29","author":"Loomba","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1038\/s41598-019-43228-0","article-title":"Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine","volume":"9","author":"Brandt","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Perumpail, B.J., Li, A.A., John, N., Sallam, S., Shah, N.D., Kwong, W., Cholankeril, G., Kim, D., and Ahmed, A. (2018). The Role of Vitamin E in the Treatment of NAFLD. Diseases, 6.","DOI":"10.3390\/diseases6040086"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"El Hadi, H., Vettor, R., and Rossato, M. (2018). Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth?. Antioxidants, 7.","DOI":"10.3390\/antiox7010012"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"Kessler","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fendo.2020.00070","article-title":"Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MAJ.0b013e318213e526","article-title":"Lipid targets during statin treatment in dyslipidemia patients affected by nonalcoholic fatty liver disease","volume":"342","author":"Maroni","year":"2011","journal-title":"Am. J. Med. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.dld.2011.12.013","article-title":"Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumor necrosis factor-\u03b1-lowering property","volume":"44","author":"Hyogo","year":"2012","journal-title":"Dig. Liver Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"172661","DOI":"10.1016\/j.ejphar.2019.172661","article-title":"Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Venetsanaki","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicenter, randomized, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients with Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1042\/CS20170175","article-title":"Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease","volume":"7","author":"Dongiovanni","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ha, J., Jang, M., Kwon, Y., Park, Y.S., Park, D.J., Lee, J.H., Lee, H.J., Ha, T.K., Kim, Y.J., and Han, S.M. (2020). Metabolomic Profiles Predict Diabetes Remission after Bariatric Surgery. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123897"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/CIRCULATIONAHA.120.052386","article-title":"Bariatric Surgery and Cardiovascular Outcomes in Patients with Obesity and Cardiovascular Disease: A Population-Based Retrospective Cohort Study","volume":"143","author":"Doumouras","year":"2021","journal-title":"Circulation"},{"key":"ref_77","first-page":"693","article-title":"Does weight loss after laparoscopic sleeve gastrectomy contribute to reduction in blood pressure?","volume":"131","author":"Diemieszczyk","year":"2021","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Sutanto, A., Wungu, C.D.K., Susilo, H., and Sutanto, H. (2021). Reduction of Major Adverse Cardiovascular Events (MACE) after Bariatric Surgery in Patients with Obesity and Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Nutrients, 13.","DOI":"10.1101\/2021.09.16.21263439"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.cgh.2008.08.012","article-title":"Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"6","author":"Mummadi","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Burza, M.A., Romeo, S., Kotronen, A., Svensson, P.A., Sj\u00f6holm, K., Torgerson, J.S., Lindroos, A.K., Sj\u00f6str\u00f6m, L., Carlsson, L.M., and Peltonen, M. (2013). Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060495"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2006.01.042","article-title":"Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease","volume":"130","author":"Klein","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s11695-014-1489-2","article-title":"Effect of Roux-en-y Gastric Bypass on Nonalcoholic Fatty Liver Disease Evaluated Through NAFLD Fibrosis Score: A Prospective Study","volume":"25","author":"Cazzo","year":"2015","journal-title":"Obes. Surg."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Pedersen, J.S., Rygg, M.O., Serizawa, R.R., Kristiansen, V.B., Albrechtsen, N.J.W., Gluud, L.L., Madsbad, S., and Bendtsen, F. (2021). Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173783"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/oby.2005.140","article-title":"Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease","volume":"13","author":"Clark","year":"2005","journal-title":"Obes. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpeds.2017.10.036","article-title":"Laparoscopic Sleeve Gastrectomy Improves Nonalcoholic Fatty Liver Disease-Related Liver Damage in Adolescents by Reshaping Cellular Interactions and Hepatic Adipocytokine Production","volume":"194","author":"Nobili","year":"2018","journal-title":"J. Pediatr."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.metabol.2019.07.002","article-title":"Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation","volume":"99","author":"Fibla","year":"2019","journal-title":"Metabolism"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/jgh.15029","article-title":"Effect of weight loss induced by laparoscopic sleeve gastrectomy on liver histology and serum adipokine levels","volume":"35","author":"Salman","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.soard.2019.09.060","article-title":"Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria","volume":"15","author":"Baldwin","year":"2019","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/s00464-019-07017-0","article-title":"Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease","volume":"34","author":"Cherla","year":"2020","journal-title":"Surg. Endosc."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1007\/s11695-021-05412-y","article-title":"Gastric Bypass Compared with Sleeve Gastrectomy for Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis","volume":"31","author":"Tustumi","year":"2021","journal-title":"Obes. Surg."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00464-017-5846-9","article-title":"How bariatric surgery affects liver volume and fat density in NAFLD patients","volume":"32","author":"Luo","year":"2018","journal-title":"Surg. Endosc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1053\/j.gastro.2009.04.052","article-title":"Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease","volume":"137","author":"Mathurin","year":"2009","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/24\/5721\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:42:22Z","timestamp":1760168542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/24\/5721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,7]]},"references-count":93,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["jcm10245721"],"URL":"https:\/\/doi.org\/10.3390\/jcm10245721","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,7]]}}}